Valneva Withdraws Chikungunya Vaccine BLA/IND in U.S. Following FDA Suspension and Clinical Hold

summarizeSummary

Valneva has voluntarily withdrawn its U.S. Biologics License Application and Investigational New Drug application for its chikungunya vaccine, IXCHIQ®, after an FDA license suspension and a new clinical hold due to a serious adverse event.

check_boxKey Events

• U.S. Regulatory Withdrawal

  Valneva voluntarily withdrew its Biologics License Application (BLA) and Investigational New Drug (IND) for its chikungunya vaccine, IXCHIQ®, in the United States.

• FDA Actions

  This withdrawal follows an FDA suspension of the IXCHIQ® license in August 2025 and a new clinical hold placed on the IND due to a serious adverse event.

• Serious Adverse Event (SAE)

  A newly reported foreign SAE involved a younger adult who received IXCHIQ® and two other vaccines. Causality is not yet determined but may be plausibly related to IXCHIQ® vaccination.

• Global Product Opportunity Review

  Valneva continues to engage with health authorities in Europe, Canada, the UK, and Brazil where IXCHIQ® is licensed, while reviewing the global product opportunity.

auto_awesomeAnalysis

The voluntary withdrawal of IXCHIQ®'s Biologics License Application (BLA) and Investigational New Drug (IND) in the U.S., prompted by an FDA license suspension and a subsequent clinical hold due to a newly reported Serious Adverse Event (SAE), represents a significant setback for Valneva. This action effectively halts the company's path to commercialization for this vaccine in the critical U.S. market. While causality for the SAE is undetermined, the FDA's actions underscore serious regulatory concerns that could impact the vaccine's global prospects and investor confidence. Investors should monitor further updates on the SAE investigation and the vaccine's status in other licensed territories.